ADMA Biologics reported a strong third quarter of 2025, with total revenue reaching $134.2 million, showcasing solid sequential and year-over-year growth driven by record utilization of ASCENIV and operational advancements.
- Total revenue increased 10% quarter-over-quarter and 12% year-over-year to $134.2 million.
- GAAP net income rose to $36.4 million, a 6% increase from the previous quarter and 1% year-over-year.
- Adjusted EBITDA grew by 16% quarter-over-quarter and 29% year-over-year to $58.7 million, indicating enhanced operational leverage.
- ASCENIV observed significant patient-driven demand, with promising payer negotiations expected to improve reimbursement access in 2026.
- Operational advancements, including FDA regulatory approval for yield-enhanced production, are projected to enhance gross margins substantially starting Q4 2025.
Community Discussion